DelveInsight’s Fabry Disease Market Insights report includes a comprehensive understanding of current treatment practices, Fabry disease emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan].

 

Key Takeaways from the Fabry Disease Market Research Report

• The total Fabry Disease market size in the 7MM is approximately USD 1,306 million in 2022 and is projected to increase during the forecast period (2023-2032)
• Among EU countries, the UK and Italy account for the maximum market size of USD 158, and USD 150 million in 2022 while Spain occupies the bottom of the ladder in the same year with USD 44 million.
• Japan accounts for a market size of USD 125 million in 2022, but these dynamics are expected to change in the forecast period.
• There were 15,200+ diagnosed prevalent cases of Fabry Disease estimated to have occurred in the 7MM in 2022 of which 8,300+ of the accounted cases were estimated to be from the US alone and these cases are anticipated to increase during the forecast period.
• The diagnosed prevalent cases of Fabry Disease were further divided into Phenotype-specific cases. The Phenotype-specific diagnosed prevalent cases of Fabry Disease are categorized into Classic and Late-onset with 6,900+, and 8,300+ cases respectively in the 7MM in 2022 which will further increase in 2032.

 

Discover which therapies are expected to grab the major Fabry disease market share @ Fabry Disease Market Size Report

 

Fabry Disease Overview

Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body. Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.

 

Fabry Disease Epidemiology Segmentation

• Prevalent Cases of Fabry Disease
• Age-specific Cases of Fabry Disease
• Gender-specific Cases of Fabry Disease
• Diagnosed Cases of Fabry Disease
• Phenotype-specific cases
• Treated Cases

 

Download the report to understand which factors are driving Fabry disease epidemiology trends @ Fabry Disease Epidemiological Insights

 

Fabry Disease Treatment Market

Fabry disease treatment includes enzyme replacement therapy (ERT), oral chaperone therapy, and adjunctive treatment such as ACE inhibitors or angiotensin receptor blockers, antiplatelet drugs, and analgesics. Studies have shown ERT to delay, but not always prevent, some clinical complications of FD. Currently, effective Fabry disease management necessitates a multidisciplinary approach that includes intravenous ERT or chaperone therapy, as well as adjunct therapies such as lifestyle modifications and prophylactic medications.

 

Fabry Disease Pipeline Therapies and Key Companies

• PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
• Venglustat: Sanofi Genzyme
• ST-920: Sangamo Therapeutics
• FLT190: Freeline Therapeutics
• 4D-310: 4D Molecular Therapeutics
• Lucerastat: Idorsia Pharmaceuticals
• Moss-aGal: GREENOVATION BIOTECH GMBH

 

To know more about Fabry disease medication, visit @ Fabry Disease Treatment Market

 

Fabry Disease Market Dynamics

To counter the current unmet needs of the Fabry disease market and to provide better treatment options, several companies are working aggressively to develop new therapies with novel mechanisms of action. In addition, many therapies are being studied in various stages of clinical trials. Pegylated forms of -GAL, gene therapy, and substrate reduction therapy are examples of these. 

 

Learn more about the FDA-approved drugs for Fabry disease treatment @ Drugs for Fabry Disease Treatment

 

Scope of the Fabry Disease Market Report

• Therapeutic Assessment: Fabry Disease’s current marketed and emerging therapies
• Fabry Disease Market Dynamics: Fabry Disease market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Fabry Disease Market Access and Reimbursement

 

Discover more about drugs for Fabry disease in development @ Fabry Disease Clinical Trials

 

Table of Content

1. Key Insights

2. Fabry Disease Market Report Introduction

3. Fabry Disease Market Overview At A Glance

4. Fabry Disease Epidemiology And Market Forecast Methodology

5. Key Events

6. Executive Summary Of Fabry Disease

7. Fabry Disease Market Disease Background And Overview

8. Fabry Disease Epidemiology And Patient Population

9. Fabry Disease Patient Journey

10. Fabry Disease Marketed Drugs

11. Fabry Disease Emerging Drugs

12. Fabry Disease: Seven Major Market Analysis

13. Key Opinion Leaders’ Views

14. Fabry Disease Swot Analysis

15. Fabry Disease Unmet Needs

16. Fabry Disease Market Access And Reimbursement

17. Appendix

18. Delveinsight Capabilities

19. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services